Physician profile
Bahram Redjaee
NPI 1073504700
$6,202.68
in general payments reported to CMS, 2019-2025
20 companies · $1,335 in 2025
The $1,335 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $593 · 2021: $697 · 2022: $1,110 · 2023: $1,030 · 2024: $1,104 · 2025: $1,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,103 · Education: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,103.47 |
| Education | $364.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,136.52 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $990.52 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Jazz Pharmaceuticals INC. | $784.48 | 2020-2025 | |
| Mylan Specialty L.P. | $647.89 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $323.62 | 2021-2025 | Dupixent |
| Genzyme Corporation | $232.15 | 2022-2025 | |
| Axsome Therapeutics, INC. | $182.57 | 2023-2025 | Sunosi |
| Electromed, INC. | $157.18 | 2022-2025 | Smartvest |
| Amgen INC. | $149.86 | 2022-2024 | Tezspire |
| Inspire Medical Systems, INC. | $134.46 | 2022 | |
| Viatris Specialty LLC | $85.77 | 2025 | Yupelri |
| Lilly USA, LLC | $84.62 | 2025 | Zepbound |
| Sanofi-Aventis U.S. LLC | $74.75 | 2023 | |
| Grifols USA, LLC | $51.99 | 2022-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.56 | 2019-2024 | Ofev |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $40.91 | 2025 | |
| Verona Pharma, INC. | $23.08 | 2025 | Ohtuvayre |
| Avadel Cns Pharmaceuticals, LLC | $20.43 | 2025 | Lumryz |
| Teva Pharmaceuticals USA, INC. | $16.88 | 2020 | |
| Nabriva Therapeutics, Plc | $14.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bahram Redjaee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.